EUNCL Kick-off

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory

30.06.2015

Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval

GRENOBLE, France – June 30, 2015 – CEA-Leti today announced the launch of the European Nano-Characterisation Laboratory (EUNCL) funded by the European Union’s Horizon 2020 research and innovation programm e. Its main objective is to reach a level of international excellence in nanomedicine characterisation for medical indications like cancer, diabetes, inflammatory diseases or infections, and make it accessible to all organisations developing candidate nanomedicines prior to their submission to regulatory agencies to get the approval for clinical trials and, later, marketing authorization.

“As reported in the ETPN White Paper , there is a lack of infrastructure to support nanotechnology-based innovation in healthcare,” said Patrick Boisseau, head of business development in nanomedicine at CEA-Leti and chairman of the European Technology Platform Nanomedicine (ETPN). “Nanocharacterisation is the first bottleneck encountered by companies developing nanotherapeutics. The EUNCL project is of most importance for the nanomedicine community, as it will contribute to the competiveness of nanomedicine products and tools and facilitate regulation in Europe.”

EUNCL is partnered with the sole international reference facility, the Nanotechnology Characterization Lab of the National Cancer Institute in the U.S. (US-NCL) , to get faster international harmonization of analytical protocols.

“We are excited to be part of this cooperative arrangement between Europe and the U.S.,” said Scott E. McNeil, director of U.S. NCL. “We hope this collaboration will help standardize regulatory requirements for clinical evaluation and marketing of nanomedicines internationally. This venture holds great promise for using nanotechnologies to overcome cancer and other major diseases around the world.”

EUNCL is also closely connected to national medicine agencies and the European Medicines Agency to continuously adapt its analytical services to requests of regulators. EUNCL is designed, organized and operated according to the highest EU regulatory and quality standards.

This project is important for Europe, as it will be the first transnational infrastructure in nano-medicine. It aims at fostering innovation by sharing knowledge and technologies between academia and industry.

The mission of EUNCL is:

  • To provide a trans-disciplinary testing infrastructure covering a comprehensive set of preclinical characterisation assays (physical, chemical, in-vitro and in-vivo biological testing), allowing researchers to fully comprehend the biodistribution, metabolism, pharmacokinetics, safety profiles and immunological effects of their medicinal nano-products.
  • To foster the use and deployment of standard operating procedures (SOPs), benchmark materials and quality management for the preclinical characterisation of medicinal nano-products.
  • To promote intersectoral and interdisciplinary communication among key drivers of innovation, especially between developers and regulatory agencies.

This project, led by CEA-Tech (Leti and Liten, FR), brings together nine partners from eight countries:

  • Joint Research Centre - European Commission (IT)
  • European Research Services GmbH (DE),
  • Leidos Biomedical Research, Inc. (U.S.)
  • Trinity College Dublin (IE)
  • Stiftelsen SINTEF (NO)
  • University of Liverpool (UK)
  • EMPA (CH) and
  • Gesellschaft für Bioanalytik Münster (GE).

Within EU-NCL, six analytical facilities will offer transnational access to their existing analytical services for public and private developers, and will also develop new or improved analytical assays to keep EU-NCL at the cutting edge of nanomedicine characterisation.

EUNCL is funded by the European Commission for a four-year period, with nearly 5 million euros allocated.

About CEA-Leti (France)

As one of three advanced-research institutes within the CEA Technological Research Division, CEA-Leti serves as a bridge between basic research and production of micro- and nanotechnologies that improve the lives of people around the world. It is committed to creating innovation and transferring it to industry. Backed by its portfolio of 2,800 patents, Leti partners with large industrials, SMEs and startups to tailor advanced solutions that strengthen their competitive positions. It has launched 54 startups. Its 8,500m² of new-generation cleanroom space feature 200mm and 300mm wafer processing of micro and nano solutions for applications ranging from space to smart devices. With a staff of more than 1,800, Leti is based in Grenoble, France, and has offices in Silicon Valley, Calif., and Tokyo. Follow us on www.leti.fr and @CEA_Leti.

Press contacts

Agency +33 6 74 93 23 47
Email: sldampoux@mahoneylyle.com

Events where you meet EUNCL

More Events ...

European Nanomedicine Characterisation Laboratory (EUNCL)

Call for Proposals!

News

  • EUNCL ExBo Meeting in Liverpool
    The EUNCL ExBo met on 22nd and 23rd November 2018 at University of Liverpool to discuss the actual status of the work in the project and especially in the TNA. The CET and TNA management updated the ExBo on the on-going and the further work planned. The discussion on all questions raised during the meeting was very extensive and important decisions were taken for the last year of the project duration.
  • CLINAM 2018 with EUNCL Participation
    It was the 11th Summit of its kind. CLINAM again welcomed the participants from the community of nanomedicine, targeted drug delivery and precision medicine and bring together the pioneers and worldwide opinion leaders, not only to learn and discuss but also to develop new ideas, create new collaborative projects and shape the future of medicine.
  • Trainee position at JRC (5 months)
    The Consumer Products Safety Unit (F.2), part of Health, Consumers and Reference Materials Directorate-F at the JRC in Ispra (Italy), is looking for a trainee for the Nanobiotechnology laboratory.

More News ...